⌘K
Loading ticker…
As of 2026-08-24, Moleculin Biotech, Inc. (MBRX) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 23. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 36.4%, relative volume 0.17×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MBRX is in a stage 4 downtrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -65.9% / -82.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
MBRX appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $32K notional.
Held by 1 ETFs · $32K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $32K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MBRX Jan avg: -1.00% median: 3.84% win: 50% σ: 31.92% n: 4 2022-04-12 → 2026-07-31 | MBRX Feb avg: -9.50% median: -9.26% win: 25% σ: 28.54% n: 4 2022-04-12 → 2026-07-31 | MBRX Mar avg: -21.68% median: -22.59% win: 0% σ: 13.68% n: 4 2022-04-12 → 2026-07-31 | MBRX Apr avg: -6.49% median: -15.06% win: 40% σ: 15.63% n: 5 2022-04-12 → 2026-07-31 | MBRX May avg: -6.96% median: -5.66% win: 20% σ: 10.59% n: 5 2022-04-12 → 2026-07-31 | MBRX Jun avg: -20.69% median: -8.63% win: 0% σ: 26.90% n: 5 2022-04-12 → 2026-07-31 | MBRX Jul avg: 7.56% median: 9.40% win: 60% σ: 69.27% n: 5 2022-04-12 → 2026-07-31 | MBRX Aug avg: -20.14% median: -15.74% win: 0% σ: 12.06% n: 4 2022-04-12 → 2026-07-31 (current) | MBRX Sep avg: -1.40% median: -6.14% win: 50% σ: 30.09% n: 4 2022-04-12 → 2026-07-31 | MBRX Oct avg: -3.79% median: -7.06% win: 25% σ: 10.30% n: 4 2022-04-12 → 2026-07-31 | MBRX Nov avg: 8.79% median: 16.28% win: 75% σ: 36.79% n: 4 2022-04-12 → 2026-07-31 | MBRX Dec avg: -18.27% median: -32.51% win: 25% σ: 42.35% n: 4 2022-04-12 → 2026-07-31 |